GlassScriptPhysician profile
Divya Janardhanan
NPI 1043666423
$6,795.83
in general payments reported to CMS, 2019-2025
31 companies · $1,206 in 2025
The $1,206 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $196 · 2021: $816 · 2022: $1,319 · 2023: $1,060 · 2024: $2,198 · 2025: $1,206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,191 · Travel and Lodging: $149 · Consulting Fee: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,190.85 |
| Travel and Lodging | $149.03 |
| Consulting Fee | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,369.66 | 2021-2025 | Proclaim, Eterna, Octrode |
| Boston Scientific Corporation | $1,012.46 | 2021-2025 | Intracept, Accolade Sr |
| Painteq LLC | $849.39 | 2022-2024 | Painteq |
| Collegium Pharmaceutical, INC. | $674.83 | 2022-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $438.03 | 2021-2025 | Relistor |
| Nalu Medical, INC. | $408.08 | 2022-2025 | Nalu Neurostimulation System |
| Medtronic, INC. | $369.06 | 2021-2024 | V-Loc 180, Intellis Adaptivestim, Synchromedii |
| Nevro Corp. | $310.91 | 2020-2024 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $203.60 | 2022 | |
| Curonix LLC | $197.86 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Abbvie INC. | $174.32 | 2021-2023 | |
| Vertos Medical, INC. | $161.51 | 2024 | Mild Device Kit |
| Biotronik Nro, INC. | $80.76 | 2025 | Prospera |
| Vertex Pharmaceuticals Incorporated | $56.62 | 2025 | |
| Spr Therapeutics, INC | $55.02 | 2024-2025 | Sprint Pns System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $52.61 | 2020 | |
| Grt US Holding, INC. | $52.41 | 2022 | |
| Averitas Pharma INC. | $45.95 | 2023-2025 | Qutenza |
| Arbor Pharmaceuticals, INC. | $38.80 | 2021-2022 | |
| Valinor Pharma, LLC | $28.95 | 2025 | Movantik |
| Stryker Corporation | $27.26 | 2020 | |
| Bioventus LLC | $26.30 | 2023 | Supartz Fx Sodium Hyaluronate |
| Saluda Medical Americas, INC. | $22.35 | 2024 | Evoke |
| Amgen INC. | $21.75 | 2022 | |
| Scilex Pharmaceuticals INC. | $21.53 | 2023 | Ztlido |
| Avanos Medical | $18.76 | 2021 | |
| Ibsa Pharma INC. | $18.45 | 2024 | Licart, Tirosint |
| Biodelivery Sciences International, INC. | $18.06 | 2021 | |
| Depuy Synthes Sales INC. | $14.85 | 2022 | |
| Azurity Pharmaceuticals, INC. | $13.84 | 2023 | Horizant |
| Mml US, INC. | $11.85 | 2025 | Reactiv8 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Janardhanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.